Drug Discovery and Development Platform

Drug Discovery and Development Platform

The Drug Discovery and Development Platform was established at SciLifeLab in 2013, as a national Swedish infrastructure for academic drug discovery and development. We support integrated drug discovery and development projects utilizing the facilities and expertise within the platform – which represent a minimal toolbox for early drug discovery. We also offer services from the individual facilities in projects related to drug discovery and development to the Swedish research community.

Description

The Drug Discovery and Development Platform was established at SciLifeLab in 2013 through specific governmental support to establish a national Swedish infrastructure for academic drug discovery and development. Our first priority is to support integrated drug discovery and development projects utilizing most of the facilities within the platform – which represent a minimal toolbox of infrastructure and expertise needed for early drug discovery. As a second priority, we offer service from the individual facilities in projects related to drug discovery and development.

We encourage all academic researchers with an interest in turning their discoveries into cures for patients to contact us for an open discussion. 

Services

SciLifeLab DDD offers integrated drug discovery efforts to the Swedish academic research community. We help prepare projects for review by the national platform board that makes final prioritization of projects entering the platform. Upon entry, we work together with the research group to add industrial drug discovery and development expertise to the project. We offer industry standard infrastructure, expertise, and strategic support to help progress projects towards a pre-clinical proof-of-concept. The drug leads can be either a small molecule drug or a human antibody therapeutic. Services are offered in the following areas: protein production, human antibody therapeutics, biochemical and cellular screening, medicinal and computational chemistry, DMPK (drug metabolism and pharmacokinetics), in vitro and systems pharmacology, as well as biophysical methods for molecular interaction studies. In addition to that, we plan to put in place a national infrastructure for compound logistics and data management in collaboration with Chemical Biology Consortium Sweden. The researcher/customer retains all rights and ownership during this process.

Participating Facilities in the DDD platform;

  • ADME (Absorption Distribution, Metabolism Excretion) of Therapeutics (UDOPP)
  • In Vitro and Systems Pharmacology
  • Biophysical Screening and Characterization
  • Medicinal Chemistry – Lead Identification
  • Medicinal Chemistry – Hit2Lead
  • Biochemical and Cellular Screening
  • Human Antibody Therapeutics (Hosting the SciLifeLib phage display libraries)
  • Protein Expression and Characterization
  • Compound Center (Hosting the SciLifeLab compound collection)

Practical information

Please contact us for further information. 

Interested in Industry collaboration
Tomtebodavägen 23A
171 65 Solna
+46 (0)8 524 813 98